Making Vaccine and Biotherapeutic Production Fast and Affordable

Mark Emalfarb, president and CEO of Dyadic, discusses the company’s fungal-based manufacturing platform, how it can product large volumes of enzymes and other proteins in a fast and cost-effective manner, and the potential this has to change the way biologics are manufactured.